Fellows’ Journal Club
ISSUE
(3 of 3)
The authors evaluated the results reported in 23 studies that included 516 patients in whom different drugs were used for rescue therapy in thromboembolic complications during endovascular treatment of intracranial aneurysms. The literature shows that rescue therapy with thrombolytic agents resulted in significantly more morbidity than rescue therapy with glycoprotein IIb/IIIa inhibitors. Tirofiban/eptifibatide resulted in significantly higher recanalization rates compared with abciximab.
Abstract
BACKGROUND AND PURPOSE
Intraprocedural thrombus formation during endovascular treatment of intracranial aneurysms is often treated with glycoprotein IIb/IIIa inhibitors and, in some instances, fibrinolytic therapy. We performed a meta-analysis evaluating the safety and efficacy of GP IIb/IIIa inhibitors compared with fibrinolysis. We also evaluated the safety and efficacy of abciximab, an irreversible inhibitor, compared with tirofiban and eptifibatide, reversible inhibitors of platelet function.
MATERIALS AND METHODS
We performed a comprehensive literature search for studies on rescue therapy for intraprocedural thromboembolic complications with glycoprotein IIb/IIIa inhibitors or fibrinolysis during endovascular treatment of intracranial aneurysms. We studied rates of periprocedural stroke/hemorrhage, procedure-related morbidity and mortality, immediate arterial recanalization, and long-term good clinical outcome. Event rates were pooled across studies by using random-effects meta-analysis.
RESULTS
Twenty-three studies with 516 patients were included. Patients receiving GP IIb/IIIa inhibitors had significantly lower perioperative morbidity from stroke/hemorrhage compared with those treated with fibrinolytics (11.0%; 95% CI, 7.0%–16.0% versus 29.0%; 95% CI, 13.0%–55.0%; P = .04) and were significantly less likely to have long-term morbidity (16.0%; 95% CI, 11.0%–21.0% versus 35.0%; 95% CI, 17.0%–58.0%; P = .04). There was a trend toward higher recanalization rates among patients treated with glycoprotein IIb/IIIa inhibitors compared with those treated with fibrinolytics (72.0%; 95% CI, 64.0%–78.0% versus 50.0%; 95% CI, 28.0%–73.0%;P = .08). Patients receiving tirofiban or eptifibatide had significantly higher recanalization rates compared with those treated with abciximab (83.0%; 95% CI, 68.0%–91.0% versus 66.0%; 95% CI, 58.0%–74.0%; P = .05). No difference in recanalization was seen in patients receiving intra-arterial (77.0%; 95% CI, 66.0%–85.0%) or intravenous GP IIb/IIIa inhibitors (70.0%; 95% CI, 57.0%–80.0%, P = .36).
CONCLUSIONS
Rescue therapy with thrombolytic agents resulted in significantly more morbidity than rescue therapy with glycoprotein IIb/IIIa inhibitors. Tirofiban/eptifibatide resulted in significantly higher recanalization rates compared with abciximab.
